Invion Ltd (ASX: IVX) Share Price and News

Ms Leydin has over 30 years' experience in the accounting profession and over 20 years' experience holding Board positions including Company Secretary and CFO of ASX listed entities. She has experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, reorganisation of Companies, initial public offerings, secondary raisings and shareholder relations.

Mr Chew has over 25 years' experience in healthcare biotech, investing and transforming business operations. He is also Co-Founder of Chronic Airway Therapeutics. e also held a number of positions in KPMG across Asia Pacific including Director at KPMG Consulting (Singapore and Sydney).

Mr Yamashita is an experienced corporate consultant and investment professional, with over 40 years' experience in investment management, investment banking and alternative investment throughout the APAC region. From 1999 to 2005, He was President and CEO of Search Investment Group and founding CEO and CIO of Search Alternative Investment Ltd (SAIL). Prior to Search Investments Group, He was Managing Director and Head of Asia Capital Markets for Merrill Lynch from 1996 to 1998. He is Managing Partner at Polar Ventures and has held numerous positions as a 16-year veteran of Goldman Sachs and an advisor to various companies, including Plantation Timber Partners, Wuhan; Duty Free Shoppers, Asia; TVSN, Shanghai; and Mizuho Alternative Investments LLC. He is the member of the Risk Committee.

Mr Field brings more than 30 years of experience in the global biopharmaceutical industry, across commercialisation, investment and strategic partnering of new drug candidates and therapeutic programs. Mr Field is currently a NED at 60 Degrees Pharmaceuticals the Executive Chair of Wintermute Biomedical Inc. and Head of Business Development at Alsonex Pty Ltd. He previously held positions at Neurizon Therapeutics Ltd., Horizon 3 Healthcare Fund and other biotech companies and organisations.